HRS 5965
Alternative Names: HRS-5965Latest Information Update: 01 Jul 2025
At a glance
- Originator Chengdu Suncadia Medicine
- Class Anti-inflammatories; Urologics
- Mechanism of Action Complement factor B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Paroxysmal nocturnal haemoglobinuria
- Phase II IgA nephropathy
- Phase I Glomerulonephritis
Most Recent Events
- 30 Jun 2025 Chengdu Suncadia Medicine plans a phase I trial for IgA Nephropathy and Paroxysmal nocturnal haemoglobinuria (In volunteers) in China (PO) in June 2025 (NCT07035665)
- 27 Jun 2025 Chengdu Suncadia Medicine plans to initiate a phase I trial for Complement Mediated Glomerular Diseases and Hemolytic Anemia (In volunteers) in China (PO) (NCT07040787)
- 11 Jun 2025 Chengdu Suncadia Medicine plans phase III in IgA-nephropathy (PO) (NCT07014826)